A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-Induced Mild Asthma (ARORAGE-2001)
Allergy | Asthma Symptoms and SignsThis study is for patients with allergic asthma. Asthma can cause the airways of the lungs to narrow (airways are the tubes which carry air into the lungs). This can cause wheezing, shortness of breath, chest tightness and/or cough. This airway narrowing is often due to chronic inflammation in the lungs.
The investigational study drug (known as ARO-RAGE) is being developed to treat asthmatics by reducing the amount of a protein in the lung (called Receptor for Advanced Glycation End-products, or RAGE). The RAGE protein may cause inflammation in the lung airways, so it is possible that ARO-RAGE will decrease this inflammation. This may result in better airflow, improved symptoms, and fewer asthma flare-ups (exacerbations). It is also possible that you may receive no benefit and it may not result in these improved symptoms.
null
Participation Requirements
-
Sex:
Male, Female, Intersex -
Eligible Ages:
18 to 65
Participation Criteria
Inclusion Criteria:
1. You are 18-65 years old
2. You have allergic asthma (your asthma flares up only with exposure to allergic triggers, such as animals or pollen).
Exclusion Criteria:
1. You are pregnant, or plan to become pregnant.
2. You have significant health issues other than asthma.
Study Location
University of Calgary
University of CalgaryCalgary, Alberta
Canada
Contact Study Team
- Study Sponsored By
- University of Calgary
- Participants Required
- More Information
- Study ID:
REB25-1806